{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:31:16Z","timestamp":1786120276391,"version":"build-2736575974"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1097\/jcp.0b013e318234ee66","type":"journal-article","created":{"date-parts":[[2011,10,21]],"date-time":"2011-10-21T04:09:11Z","timestamp":1319170151000},"page":"712-716","source":"Crossref","is-referenced-by-count":18,"title":["Usefulness of NT-Pro-BNP and Echocardiography in the Diagnosis of Subclinical Clozapine-Related Cardiotoxicity"],"prefix":"10.1097","volume":"31","author":[{"given":"Carlo","family":"Rostagno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Domenichetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Pastorelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Franco","family":"Gensini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20210128","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0140-6736(09)60742-X","article-title":"11- year follow-up of mortality in patients with schizophrenia: a population based cohort study (FIN 11 study).","volume":"374","author":"Tihonen","year":"2009","journal-title":"Lancet"},{"key":"R2-6-20210128","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1136\/bmj.321.7273.1360","article-title":"Atypical antipsychotics. Patients value the lower incidence of extrapiramidal side effects.","volume":"321","author":"Kapur","year":"2000","journal-title":"BMJ"},{"key":"R3-6-20210128","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1136\/bmj.321.7273.1371","article-title":"Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis.","volume":"321","author":"Geddes","year":"2000","journal-title":"BMJ"},{"key":"R4-6-20210128","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1001\/archpsyc.60.1.82","article-title":"Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT).","volume":"60","author":"Meltzer","year":"2003","journal-title":"Arch Gen Psychiatry"},{"key":"R5-6-20210128","first-page":"295","article-title":"Clozapine-induced agranulocytosis: genetic risk factors and an immunologic explanatory model.","volume":"48","author":"Guzelcan","year":"2006","journal-title":"Tijdschr Psychiatr"},{"key":"R6-6-20210128","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1016\/S0140-6736(99)10385-4","article-title":"Myocarditis and cardiomyopathy associated with clozapine.","volume":"354","author":"Killian","year":"1999","journal-title":"Lancet"},{"key":"R7-6-20210128","first-page":"4151","article-title":"Allergic myocarditis in clozapine treatment.","volume":"156","author":"Jensen","year":"1994","journal-title":"Ugeskrift for Laeger"},{"key":"R8-6-20210128","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/01.jcp.0000150217.51433.9f","article-title":"Adverse cardiac effects associated with clozapine.","volume":"25","author":"Merril","year":"2005","journal-title":"J Clin Psychopharmacol"},{"key":"R9-6-20210128","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1080\/j.1440-1614.2004.01481.x","article-title":"Clozapine related myocarditis and cardiomyopathy in an Australian metropolitan psychiatric service.","volume":"38","author":"Reinders","year":"2004","journal-title":"Austr NZ Psychiatry"},{"key":"R10-6-20210128","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2165\/00002018-200730010-00005","article-title":"Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993-2003.","volume":"30","author":"Haas","year":"2007","journal-title":"Drug Saf"},{"key":"R11-6-20210128","doi-asserted-by":"crossref","first-page":"304","DOI":"10.4088\/JCP.08m04718yel","article-title":"Cardiovascular disease mortality in patients with chronic schizophrenia treated with clozapine: a retrospective cohort study.","volume":"71","author":"Kelly","year":"2010","journal-title":"J Clin Psychiatry"},{"key":"R12-6-20210128","first-page":"353","article-title":"An analysis of the time-relations of electrocardiograms.","volume":"7","author":"Bazett","year":"1920","journal-title":"Heart"},{"key":"R13-6-20210128","first-page":"1140","article-title":"Recommendations for chamber quantification: a report from the American Society of Echocardiography's guidelines and standard committee and the chamber quantification working group, developed in conjunction with the European Society of Echocardiography, a branch of European Society of Cardiology.","volume":"18","author":"Lang","year":"2005","journal-title":"Am J Echocardiogr"},{"key":"R14-6-20210128","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.euje.2005.12.014","article-title":"Recommendations for chamber quantification.","volume":"7","author":"Lang","year":"2006","journal-title":"Eur J Echocardiogr"},{"key":"R15-6-20210128","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJM200107193450317","article-title":"Myocarditis and cardiomyopathy associated with clozapine in the United States.","volume":"345","author":"La Grenade","year":"2001","journal-title":"N Engl J Med"},{"key":"R16-6-20210128","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1365-2710.2004.00616_1.x","article-title":"Myocarditis and cardiomyopathy in patients treated with clozapine.","volume":"30","author":"Wehemeier","year":"2005","journal-title":"J Clin Pharmacol Ther"},{"key":"R17-6-20210128","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1177\/106002809603000606","article-title":"Cardiomyopathy associated with clozapine.","volume":"30","author":"Leo","year":"1996","journal-title":"An Pharmacother"},{"key":"R18-6-20210128","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1016\/j.bcp.2004.02.017","article-title":"Inverse agonist properties of atypical antipsychotic drugs.","volume":"67","author":"Akem","year":"2004","journal-title":"Biochem Pharmacol"},{"key":"R19-6-20210128","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ejphar.2008.06.088","article-title":"Clozapine-induced myocarditis: role of catecholamines in a murine model.","volume":"592","author":"Wang","year":"2008","journal-title":"Eur J Pharmacol"},{"key":"R20-6-20210128","first-page":"167","article-title":"Association of autonomic dysfunction and clozapine heart rate variability and risk of sudden death in patients with schizophrenia on long-term psychotropic medications.","volume":"179","author":"Cohen","year":"2001","journal-title":"Br J Pharmacol"},{"key":"R21-6-20210128","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/sj.bjp.0706744","article-title":"Blockade of HERG human K+ channels and IKr of guinea-pig cardiomyocytes by the antipsychotic drug clozapine.","volume":"148","author":"Kim","year":"2006","journal-title":"Br J Pharmacol"},{"key":"R22-6-20210128","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1540-8159.1996.tb04796.x","article-title":"Tachycardiomyopathy: mechanisms and clinical implications.","volume":"19","author":"Fenelon","year":"1996","journal-title":"Pacing Clin Electrophysiol"},{"key":"R23-6-20210128","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1136\/hrt.2003.017129","article-title":"Tachycardiomyopathy: a diagnosis not to be missed.","volume":"90","author":"Walker","year":"2004","journal-title":"Heart"},{"key":"R24-6-20210128","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.genhosppsych.2007.09.003","article-title":"Beta-blocker and angiotensin-converting enzyme inhibitor may limit certain cardiac adverse effects of clozapine.","volume":"30","author":"Rostagno","year":"2008","journal-title":"Gen Hosp Psychiatry"},{"key":"R25-6-20210128","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1021\/tx034035z","article-title":"Bioactivation of clozapine by murine cardiac tissue in vivo and in vitro.","volume":"16","author":"Williams","year":"2003","journal-title":"Chem Res Toxicol"},{"issue":"suppl 1","key":"R26-6-20210128","first-page":"1","article-title":"Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review.","volume":"19","author":"Newcomer","year":"2005","journal-title":"CNS Drugs"},{"key":"R27-6-20210128","first-page":"747","article-title":"Successful re-challenge with clozapine following development of clozapine-induced cardiomyopathy.","volume":"42","author":"Floreani","year":"2008","journal-title":"Aust N Z J Psychiatry"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00004714-201112000-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:24:17Z","timestamp":1786047857000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00004714-201112000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0b013e318234ee66","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}